News Room
TP-102 Phase 2b End of Study Marks Key Step Toward Phase 3 Development
We are pleased to share that last Friday marked an important milestone for Technophage with the End of Study of the TP-102 Phase 2b clinical trial....
Technophage Awarded PME Excelência 2024 Status
We are proud to share that Technophage has been awarded the 'PME Excelência 2024' status. This recognition highlights companies with strong...
Technophage Reaches Last Patient First Visit in REVERSE 2 Trial for TP-102
We are thrilled to share a major milestone in Technophage’s TP-102 clinical trial – REVERSE 2 – with the Last Patient First Visit (LPFV) now...
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology